Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data - Slideshow

Rocket Pharmaceuticals, Inc. (RCKT) presented a slideshow providing an overview of its Danon disease program and the RP-A501 pivotal trial.

The slideshow highlighted the unmet medical need for Danon disease, a rare genetic disorder that affects the heart and skeletal muscles.

Rocket's gene therapy approach aims to address this unmet need by targeting the underlying genetic cause of the disease.